SUBSCRIBE
SUBSCRIBE

Ultragenyx Pharmaceutical Inc.

NEWS
Deals
Who are the Top 3 Biotech Takeover Targets?
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
May 22, 2018
 · 
3 min read
 · 
Mark Terry
Deals
Novartis Buys Rare Drug Voucher for $130M From Ultragenyx
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.
December 18, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
Ultragenyx Stock Booms After Burosumab Continues to Impress in Phase III Study
Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
December 4, 2017
 · 
3 min read
 · 
Alex Keown
Business
Does Genentech Have a New Mega-Blockbuster?
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
3 Biotechs That Got Huge Boosts From Spark's FDA P
Policy
6 Biotechs Facing Make-or-Break FDA PDUFA Catalysts in November
Here’s a closer look at six drugs facing FDA decisions in November.
October 31, 2017
 · 
2 min read
 · 
Mark Terry
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Deals
Bay Area’s Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics
September 18, 2017
 · 
3 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Bay Area’s Ultragenyx Tanks as Seizure Drug Flunks Phase II Test
March 23, 2017
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
10 Biotech Stocks that Could Blow Up in Q3
July 6, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
Nine Bay Area Biotechs Vie to be the “Next Genentech”
May 24, 2016
 · 
4 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
July 12, 2023
 · 
3 min read
Drug Development
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
July 6, 2023
 · 
8 min read
Genetown
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
June 21, 2023
 · 
3 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 20, 2023
June 20, 2023
 · 
1 min read
Biotech Bay
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 7, 2023
 · 
1 min read
Drug Development
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
June 5, 2023
 · 
14 min read
Biotech Bay
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
May 19, 2023
 · 
1 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2023
May 18, 2023
 · 
2 min read
Drug Development
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
May 17, 2023
 · 
7 min read
Biotech Bay
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
May 8, 2023
 · 
6 min read
Load More